<DOC>
	<DOCNO>NCT01700335</DOCNO>
	<brief_summary>The purpose study investigate tolerability SyB L-1101 administer intravenously patient recurrent/relapsed refractory myelodysplastic syndrome , determine dose-limiting toxicity maximum tolerate dose , estimate recommend dose phase II study . Pharmacokinetics antitumor effect also investigate .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study SyB L-1101 Patients With Recurrent/Relapsed Refractory Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients must satisfy follow condition list . 1 . Patients histologically document cytologically confirm myelodysplastic syndrome ( MDS ) , find meet follow criterion basis World Health Organization ( WHO ) classification FrenchAmericanBritish ( FAB ) classification . Refractory Anemia ( RA ) ( &lt; 5 % myeloblast , &lt; 15 % ringed sideroblast ) RA Ring Sideroblasts ( RARS ) ( &lt; 5 % myeloblast , &gt; = 15 % ringed sideroblast ) RA Excess Blasts ( RAEB ) 1 ( 5 % 9 % myeloblast ) RAEB2 ( 10 % 19 % myeloblast ) RAEB transformation ( RAEBt ) ( 20 % 29 % myeloblast &lt; 25,000/mm^3 peripheral leukocyte ) Chronic myelomonocytic leukemia ( CMML ) ( 10 % 19 % myeloblast marrow , &gt; = 1,000/mm^3 peripheral monocyte , &lt; 13,000/mm^3 leukocyte ) However , RA patient must score Int2 high International prognostic scoring system ( IPSS ) . 2 . Patients low value least one blood cell lineage ( least one follow cytopenia ) . Neutrophils : &lt; 1,800/mm^3 Platelets : &lt; 100,000/mm^3 Hemoglobin : &lt; 10 g/dL 3 . Patients previous history chemotherapy ( include lenalidomide ) target disease meet follow criterion . Patients achieve complete remission , partial remission , hematologic improvement* Patients recurrence/relapse complete remission , partial remission , hematologic improvement* Patients intolerability lead discontinuation treatment development liver dysfunction , kidney dysfunction , etc. , start treatment . * Proximate therapeutic efficacy judge International Working Group ( IWG ) 2006 criterion 4 . Patients treat four week longer end previous therapy judge residual effect ( antitumor effect ) previous therapy . 5 . Patients expect survive least three month longer . 6 . Patients least 20 year old ( informed consent obtain ) . 7 . Patients score 0 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( P.S. ) . 8 . Patients adequate function major organ ( heart , lung , liver , kidney , etc. ) . Aspartate aminotransferase ( AST ) ( Glutamic oxaloacetic transaminase , GOT ) : great 3.0 time upper boundary reference range institution Alanine aminotransferase ( ALT ) ( Glutamic pyruvic transaminase , GPT ) : great 3.0 time upper boundary reference range institution Total bilirubin : 1.5 time upper boundary reference range institution Serum creatinine : 1.5 time upper boundary reference range institution ECG : abnormal finding require treatment Echocardiography : abnormal finding require treatment 9 . Patients personally sign informed consent document participation study . Patients satisfy follow condition enrol study . 1 . Patients anemia caused factor MDS ( hemolytic anemia , gastrointestinal ( GI ) bleeding , etc. ) . 2 . Patients undergone treatment active malignant tumor within past year ( except basal cell squamous cell skin cancer carcinoma situ cervix breast ) . 3 . Patients administer cytokine preparation granulocytecolony stimulate factor ( GCSF ) , erythropoietin , etc . within 14 day test enrollment study . 4 . Patients obvious infectious disease ( include viral infection ) . 5 . Patients serious complication ( liver failure , renal failure , etc. ) . 6 . Patients complicate previous history serious heart disease ( myocardial infarction , ischemic heart disease , etc . ) within past two year enrollment , cardiac arrhythmia require treatment . 7 . Patients serious gastrointestinal condition ( severe significant nausea/vomiting , diarrhea , etc. ) . 8 . Patients positive Hepatitis B surface ( HBs ) antigen HIV antibody . 9 . Patients serious bleed tendency ( disseminate intravascular coagulation ( DIC ) , internal hemorrhage , etc. ) . 10 . Ascites require active medical management include paracentesis , hyponatremia ( define serum sodium value &lt; 130 mEq/L ) . 11 . Patients administered drug clinical trial unapproved drug within three month enrollment . 12 . Patients addiction legal illegal drug , alcohol dependency . 13 . Patients pregnant may become pregnant . 14 . Patients consent follow contraceptive measure . Patients avoid sexual intercourse sexual partner use follow contraceptive method time period : male patient administration period trial six month end administration ; female patient administration period trial , second menstrual period confirm end administration ( case female patient menstrual period , two month end administration ) . •Male patient The patient always use condom . For effective contraception , recommend female partner also use contraceptive method female patient . •Female patient Female patient may become pregnant use one type follow contraceptive method . In addition , male partner always use condom . Oral contraceptive ( birth control pill ) Intrauterine device ( IUD ) Tubal ligation 15 . Other patient judge unsuitable investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>